Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BRD5648 ((R)-BRD0705) is an inactive (R)-enantiomer of BRD0705. BRD0705 is a GSK3α inhibitor (IC50: 66 nM; Kd: 4.8 μM) and can be used in acute myeloid leukemia (AML) studies.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 106.00 | |
5 mg | In stock | $ 243.00 | |
10 mg | In stock | $ 358.00 | |
25 mg | In stock | $ 598.00 | |
50 mg | In stock | $ 853.00 | |
100 mg | In stock | $ 1,180.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 258.00 |
Description | BRD5648 ((R)-BRD0705) is an inactive (R)-enantiomer of BRD0705. BRD0705 is a GSK3α inhibitor (IC50: 66 nM; Kd: 4.8 μM) and can be used in acute myeloid leukemia (AML) studies. |
In vitro | BRD5648 does not induce changes in enzyme phosphorylation or total β-catenin protein stabilization. |
Synonyms | (R)-BRD0705 |
Molecular Weight | 321.42 |
Formula | C20H23N3O |
CAS No. | 2056261-42-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 300 mg/mL (933.36 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BRD5648 2056261-42-6 PI3K/Akt/mTOR signaling Stem Cells GSK-3 compound Glycogen synthase kinase 3 BRD0705 BRD 0705 (R)-BRD0705 BRD-0705 negative Glycogen synthase kinase-3 BRD-5648 BRD 5648 inhibit Inhibitor (R)-enantiomer control inhibitor